Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a consensus statement

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety. Methods Existing da...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Nash, Peter, Kerschbaumer, Andreas, Doerner, Thomas, Dougados, Maxime, Fleischmann, Roy M, Geissler, Klaus, McInnes, Iain, Pope, Janet E, van der Heijde, Desiree, Stoffer-Marx, Michaela, Takeuchi, Tsutomu, Trauner, Michael, Winthrop, Kevin L, de Wit, Maarten, Aletaha, Daniel, Baraliakos, Xenofon, Boehncke, Wolf-Henning, Emery, Paul, Isaacs, John D, Kremer, Joel, Lee, Eun Bong, Maksymowych, Walter P, Voshaar, Marieke, Tam, Lai-Shan, Tanaka, Yoshiya, Van den Bosch, Filip, Westhovens, Rene, Xavier, Ricardo, Smolen, Josef S
Format:	Artikel
Sprache:	eng
Schlagworte:	ACTIVE PSORIATIC-ARTHRITIS DOUBLE-BLIND EULAR RECOMMENDATIONS HERPES-ZOSTER INADEQUATE INTERLEUKIN-6 MAINTENANCE Medicine and Health Sciences MODIFYING ANTIRHEUMATIC DRUGS RECEPTOR INHIBITION RESPONSE RHEUMATOID-ARTHRITIS THERAPY VENOUS THROMBOEMBOLISM
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!